InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,633.91
(
1.02%
)
US TECH 100
20,107.19
(
0.99%
)
Dow Jones
39,721.36
(
1.09%
)
Brent Oil
85.07
(
0.02%
)
Bitcoin
57,583.40
(
-0.30%
)
Post# of 252557
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120016
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dav1234 post# 168408

Friday, 12/20/2013 3:12:45 PM

Friday, December 20, 2013 3:12:45 PM

Post# of 252557
ALIM was +63% and PSDV was +35% yesterday on news that FDA will not require a new clinical trial to satisfy the terms of the Iluvien CRL issued in October:

http://finance.yahoo.com/news/alimera-sciences-fda-enter-labeling-213000675.html

An FDA advisory committee is also no longer required.

I didn’t think the FDA would ever approve Iluvien.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up